SCHEMBL6913951

SCHEMBL6913951

NC(=O)c1ncn([C@@H]2O[C@H](COCP(=O)(O)O)[C@@H](O)[C@H]2O)n1

nearest known ligand 0.66

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.66
SMN1; SMN2 Q16637 2/20 0.66
ALDH1A1 P00352 1/20 0.66
GLA P06280 1/20 0.66
EIF4E P06730 1/20 0.66
CYP3A4 P08684 1/20 0.66
TOP1 P11387 1/20 0.66
TSHR P16473 1/20 0.66
ADORA1 P30542 1/20 0.66
THPO P40225 1/20 0.66
PMP22 Q01453 1/20 0.66
PNP P00491 3/20 0.51
ATIC P31939 2/20 0.47
FBP1 P09467 1/20 0.47
NT5E P21589 8/20 0.46
RNASEL Q05823 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ribavirin Monophosphate SCHEMBL1508870 0.87 LMNA (0.69) LMNASMN1; SMN2ALDH1A1GLAEIF4E
Ribavirin Monophosphate SCHEMBL10882076 0.87 LMNA (0.69) LMNASMN1; SMN2ALDH1A1GLAEIF4E
Ribavirin Monophosphate SCHEMBL12727825 0.87 LMNA (0.69) LMNASMN1; SMN2ALDH1A1GLAEIF4E
Ribavirin Monophosphate SCHEMBL11202379 0.87 LMNA (0.69) LMNASMN1; SMN2ALDH1A1GLAEIF4E
Ribavirin Monophosphate SCHEMBL11654617 0.86 LMNA (0.67) LMNASMN1; SMN2ALDH1A1GLAEIF4E
SCHEMBL15046105 0.85 LMNA (0.70) LMNASMN1; SMN2ALDH1A1GLAEIF4E
SCHEMBL6913914 0.85 LMNA (0.70) LMNASMN1; SMN2ALDH1A1GLAEIF4E
SCHEMBL6555263 0.85 LMNA (0.73) LMNASMN1; SMN2ALDH1A1GLAEIF4E
SCHEMBL24024420 0.85 LMNA (0.66) LMNASMN1; SMN2ALDH1A1GLAEIF4E
SCHEMBL24024421 0.85 LMNA (0.66) LMNASMN1; SMN2ALDH1A1GLAEIF4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040023901-A1 Nucleoside 5'-monophosphate mimics and their prodrugs BIOTA HOLDINGS LIMITED (AU) 2004-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040023901-A1 Nucleoside 5'-monophosphate mimics and their prodrugs MTAP, ENTPD5, PNP LMNA 4394/4885SMN1; SMN2 2624/4885ALDH1A1 2159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.